Abstract
The impact of different gemcitabine-based first-line regimens, gemcitabine plus nab-paclitaxel or S-1, on the efficacy of second-line liposomal irinotecan in patients with metastatic pancreatic cancer
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have